Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
160 hedge funds and large institutions have $1.92B invested in Spark Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 61 increasing their positions, 33 reducing their positions, and 47 closing their positions.
90% more call options, than puts
Call options by funds: $33.3M | Put options by funds: $17.5M
85% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 47
2% less funds holding
Funds holding: 163 → 160 (-3)
39% less capital invested
Capital invested by funds: $3.15B → $1.92B (-$1.23B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$161M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$39.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$29.5M |
| 4 |
JP Morgan Chase
New York
|
+$28.1M |
| 5 |
RFS
Rockefeller Financial Services
New York
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$55.1M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$54.9M |
| 3 |
O
OrbiMed
New York
|
-$38.3M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$34.7M |
| 5 |
Jennison Associates
New York
|
-$27.2M |
ONCE Hedge Fund Activity: Q4 2017 in Review
160 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q4 2017, worth a combined $1.92B — down 39% from $3.15B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of ONCE and 44 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 61 added.
The largest buyer was Wellington Management Group, adding an estimated $161M. The largest seller was Lord, Abbett & Co, cutting an estimated $55.1M.
- 160 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q4 2017, down from 163 in Q3 2017.
- Funds reported $1.92B of Spark Therapeutics, Inc. Common Stock stock for Q4 2017, down 39% quarter-over-quarter.
- 44 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q4 2017 and 47 closed out, a net change of -3 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q4 2017 was Wellington Management Group, an estimated $161M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q4 2017 was Lord, Abbett & Co, an estimated $55.1M sold.
Based on aggregated 13F filings for Q4 2017.